Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events
Zeno Fratton,1 Stefano Bighetti,2 Luca Bettolini,2 Vincenzo Maione,2 Mariachiara Arisi,2 Cinzia Buligan,1 Giuseppe Stinco,1 Enzo Errichetti1 1Department of Medicine, Institute of Dermatology, University of Udine, Udine, Friuli Venezia-Giulia, Italy; 2Dermatology Department, University of Brescia, AS...
Saved in:
| Main Authors: | Fratton Z, Bighetti S, Bettolini L, Maione V, Arisi M, Buligan C, Stinco G, Errichetti E |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-04-01
|
| Series: | Psoriasis: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/real-world-experience-of-bimekizumab-in-a-cohort-of-109-patients-over--peer-reviewed-fulltext-article-PTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II
by: Vivian Y. Shi, et al.
Published: (2025-07-01) -
Efficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights
by: Sofia Theotokoglou, et al.
Published: (2025-07-01) -
Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics
by: E. Mortato, et al.
Published: (2025-12-01) -
Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis
by: Nikki Zangenah, BA, et al.
Published: (2025-06-01) -
Effective treatment of recalcitrant palmoplantar psoriasis in a patient with skin of color using bimekizumab
by: Emily G. Tocco, BS, et al.
Published: (2025-09-01)